Tag Archives: Incyte

Healthcare Sector Ends Higher; LifePoint Hospitals (LPNT) and Momenta Pharmaceuticals (MNTA) Declare Quarterly Results – LPNT, MNTA, FVE, PCYC, INCY, PFE

Posted on February 16, 2013 by Thomas Vedder

Last trading session data of the week confirmed that healthcare sector reacted positively with +0.17% change. Pharmacyclics, Inc (NASDAQ:PCYC) and Incyte Corporation (NASDAQ:INCY) were major percentage gainer in this sector while most active stock was Pfizer Inc (NYSE:PFE).

LifePoint Hospitals, …

Posted in Healthcare, Latest Headlines | Tagged Five Star Quality Care, FVE, INCY, Incyte, LifePoint Hospitals, LPNT, MNTA, Momenta, NASDAQ:INCY, NASDAQ:LPNT, NASDAQ:MNTA, NASDAQ:PCYC, NYSE:FVE, NYSE:PFE, PCYC, PFE, Pfizer, Pharmacyclics | Comments Off

Healthcare Stock Roundup; Acadia (ACAD) Reports $86.4 Million Equity Financing while Avanir (AVNR) Fourth Quarter Loss Narrows – ACAD, AVNR, PFE, OPTR, INCY, LLY

Posted on December 13, 2012 by Thomas Vedder

Investors responded negatively to the healthcare stocks on Wednesday. Key movement were seen in Optimer Pharmaceuticals, Inc (NASDAQ:OPTR) and Incyte Corporation (NASDAQ:INCY) on percentage decliners side while Eli Lilly & Co (NYSE:LLY) was most active stock on the decliners side.…

Posted in Healthcare, Latest Headlines | Tagged ACAD, Acadia, Avanir, AVNR, Eli Lilly, INCY, Incyte, LLY, NASDAQ:ACAD, NASDAQ:AVNR, NASDAQ:INCY, NASDAQ:OPTR, NYSE:LLY, NYSE:PFE, Optimer Pharmaceuticals, OPTR, PFE, Pfizer | Comments Off

Medicines (NASDAQ:MDCO) Inks $185 Million Deal to Acquire Incline Therapeutics – MDCO, GSK, PFE, AET, JNJ, BMY, INCY, BSX, ACUR

Posted on December 12, 2012 by Geoff Noir

The Medicines Company (NASDAQ:MDCO), a provider of medicines for critical care patients worldwide, on Wednesday reported that it has decided to purchase Analgesia system ‘IONSYS’ owner Incline Therapeutics, Inc.

The Parsippany, New Jersey based company is projected to pay $185 …

Posted in Healthcare, Latest Headlines | Tagged ACUR, Acura, AET, Aetna, BMY, Boston Scientific, Bristol-Myers Squibb, BSX, GlaxoSmithKline, GSK, INCY, Incyte, JNJ, Johnson, MDCO, Medicines, NASDAQ:ACUR, NASDAQ:INCY, NASDAQ:MDCO, NYSE:AET, NYSE:BMY, NYSE:BSX, NYSE:GSK, NYSE:JNJ, NYSE:PFE, PFE, Pfizer | Comments Off

Healthcare Sectors Optimistic Momentum Stocks- WCRX, VVUS, ARNA, RMD, BPAX, INCY, AIS

Posted on April 30, 2012 by Thomas Vedder

Warner Chilcott Plc (NASDAQ:WCRX), a maker of women’s health-care and dermatology products, surged following a news data point out the firm could be the target of a takeover by German medicine maker Bayer AG (BAYN.XE).

NASDAQ:WCRX after opening at …

Posted in Healthcare, Latest Headlines | Tagged AIS, Antares Pharma, Arena Pharmaceuticals, ARNA, Biosante, BPAX, INCY, Incyte, NASDAQ:ARNA, NASDAQ:BPAX, NASDAQ:INCY, NASDAQ:VVUS, NASDAQ:WCRX, NYSE:RMD, NYSEAMEX:AIS, ResMed, RMD, Vivus, VVUS, Warner Chilcott, WCRX | Comments Off

Regeneron (NASDAQ:REGN) Raises Eylea Sales Guidance; Almost Doubles – AMGN, NVS, WPI, AMRN, INCY, AET, THC, AZN

Posted on April 26, 2012 by Geoff Noir

Regeneron Pharmaceuticals Inc almost doubled its 2012 sales estimate for recently authorized Eylea, the second time it has done so this year, as the eye drug quickly gained share from competing products.

Regeneron currently anticipates sales of $500 million to …

Posted in Healthcare, Latest Headlines | Tagged AET, Aetna, Amarin, Amgen, AMGN, AMRN, AstraZeneca, AZN, INCY, Incyte, NASDAQ:AMGN, NASDAQ:AMRN, NASDAQ:INCY, NASDAQ:REGN, Novartis, NVS, NYSE:AET, NYSE:AZN, NYSE:NVS, NYSE:THC, NYSE:WPI, Regeneron Pharmaceuticals, REGN, Tenet, THC, Watson Pharmaceuticals, WPI | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.